UBS Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Express News | Quest Diagnostics Inc : UBS Raises Target Price to $165 From $151
Earnings Preview: DGX to Report Financial Results Pre-market on October 22
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Maintains Target Price $154
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
Asia Cervical Cancer Screening Market Forecast Report 2024-2032, Featuring Profiles of Abbott Laboratories, Hologic, Becton, Siemens, Roche Diagnostics, Quest Diagnostics and Cardinal Health
Quest Diagnostics (DGX) Receives a Hold From Morgan Stanley
Express News | Quest Diagnostics Completes Acquisition of Lab Assets From Ohiohealth
Press Release: Quest Diagnostics Completes Acquisition of Lab Assets From OhioHealth
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and PDS Biotechnology (PDSB)
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
Quest Diagnostics Is Maintained at Hold by Truist Securities
Quest Diagnostics Analyst Ratings
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $165
Balancing Growth Prospects and Challenges: A Hold Recommendation for Quest Diagnostics
Quest Diagnostics To Go Ex-Dividend On October 4th, 2024 With 0.75 USD Dividend Per Share
Is Now An Opportune Moment To Examine Quest Diagnostics Incorporated (NYSE:DGX)?
Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024